Does dapagliflozin decrease epicardial adipose tissue volume and improve metabolic parameters in diabetes mellitus patients?
Dapagliflozin may reduce epicardial adipose tissue volume and improve metabolic parameters in patients with diabetes mellitus, potentially contributing to cardiovascular risk reduction.
Treatment with dapagliflozin might improve systemic metabolic parameters and decrease the EAT volume in diabetes mellitus patients, possibly contributing to risk reduction in cardiovascular events.
Sato et al. (Thu,) studied this question.